103 related articles for article (PubMed ID: 11494148)
1. STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity.
Ning ZQ; Li J; McGuinness M; Arceci RJ
Oncogene; 2001 Jul; 20(33):4528-36. PubMed ID: 11494148
[TBL] [Abstract][Full Text] [Related]
2. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells.
Ning ZQ; Li J; Arceci RJ
Blood; 2001 Jun; 97(11):3559-67. PubMed ID: 11369651
[TBL] [Abstract][Full Text] [Related]
3. The c-Kit/D816V mutation eliminates the differences in signal transduction and biological responses between two isoforms of c-Kit.
Pedersen M; Rönnstrand L; Sun J
Cell Signal; 2009 Mar; 21(3):413-8. PubMed ID: 19049823
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3'-kinase is required for growth of mast cells expressing the kit catalytic domain mutant.
Shivakrupa R; Bernstein A; Watring N; Linnekin D
Cancer Res; 2003 Aug; 63(15):4412-9. PubMed ID: 12907613
[TBL] [Abstract][Full Text] [Related]
5. STAT3 activation is required for interleukin-6 induced transformation in tumor-promotion sensitive mouse skin epithelial cells.
Yu CY; Wang L; Khaletskiy A; Farrar WL; Larner A; Colburn NH; Li JJ
Oncogene; 2002 Jun; 21(25):3949-60. PubMed ID: 12037677
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the roles of STAT1 and STAT3 signal transduction pathways in mammalian lens development.
Ebong S; Chepelinsky AB; Robinson ML; Zhao H; Yu CR; Egwuagu CE
Mol Vis; 2004 Feb; 10():122-31. PubMed ID: 14978477
[TBL] [Abstract][Full Text] [Related]
7. In vivo differentiation of mast cells from acute myeloid leukemia blasts carrying a novel activating ligand-independent C-kit mutation.
Beghini A; Cairoli R; Morra E; Larizza L
Blood Cells Mol Dis; 1998 Jun; 24(2):262-70. PubMed ID: 9714703
[TBL] [Abstract][Full Text] [Related]
8. Requirement of Stat3 signaling for HGF/SF-Met mediated tumorigenesis.
Zhang YW; Wang LM; Jove R; Vande Woude GF
Oncogene; 2002 Jan; 21(2):217-26. PubMed ID: 11803465
[TBL] [Abstract][Full Text] [Related]
9. Transforming and differentiation-inducing potential of constitutively activated c-kit mutant genes in the IC-2 murine interleukin-3-dependent mast cell line.
Hashimoto K; Tsujimura T; Moriyama Y; Yamatodani A; Kimura M; Tohya K; Morimoto M; Kitayama H; Kanakura Y; Kitamura Y
Am J Pathol; 1996 Jan; 148(1):189-200. PubMed ID: 8546206
[TBL] [Abstract][Full Text] [Related]
10. Kit/stem cell factor receptor-induced activation of phosphatidylinositol 3'-kinase is essential for male fertility.
Blume-Jensen P; Jiang G; Hyman R; Lee KF; O'Gorman S; Hunter T
Nat Genet; 2000 Feb; 24(2):157-62. PubMed ID: 10655061
[TBL] [Abstract][Full Text] [Related]
11. Overexpression and constitutive activation of FLT3 induces STAT5 activation in primary acute myeloid leukemia blast cells.
Spiekermann K; Bagrintseva K; Schwab R; Schmieja K; Hiddemann W
Clin Cancer Res; 2003 Jun; 9(6):2140-50. PubMed ID: 12796379
[TBL] [Abstract][Full Text] [Related]
12. Abrogation of c-kit/Steel factor-dependent tumorigenesis by kinase defective mutants of the c-kit receptor: c-kit kinase defective mutants as candidate tools for cancer gene therapy.
Li Q; Kondoh G; Inafuku S; Nishimune Y; Hakura A
Cancer Res; 1996 Oct; 56(19):4343-6. PubMed ID: 8813120
[TBL] [Abstract][Full Text] [Related]
13. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.
Niu G; Wright KL; Huang M; Song L; Haura E; Turkson J; Zhang S; Wang T; Sinibaldi D; Coppola D; Heller R; Ellis LM; Karras J; Bromberg J; Pardoll D; Jove R; Yu H
Oncogene; 2002 Mar; 21(13):2000-8. PubMed ID: 11960372
[TBL] [Abstract][Full Text] [Related]
14. Isoforms of c-KIT differ in activation of signalling pathways and transformation of NIH3T3 fibroblasts.
Caruana G; Cambareri AC; Ashman LK
Oncogene; 1999 Sep; 18(40):5573-81. PubMed ID: 10523834
[TBL] [Abstract][Full Text] [Related]
15. Mutations in the catalytic subunit of class IA PI3K confer leukemogenic potential to hematopoietic cells.
Horn S; Bergholz U; Jücker M; McCubrey JA; Trümper L; Stocking C; Bäsecke J
Oncogene; 2008 Jul; 27(29):4096-106. PubMed ID: 18317450
[TBL] [Abstract][Full Text] [Related]
16. Signal transduction by several KIT juxtamembrane domain mutations.
Casteran N; De Sepulveda P; Beslu N; Aoubala M; Letard S; Lecocq E; Rottapel R; Dubreuil P
Oncogene; 2003 Jul; 22(30):4710-22. PubMed ID: 12879016
[TBL] [Abstract][Full Text] [Related]
17. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade.
Beghini A; Bellini M; Magnani I; Colapietro P; Cairoli R; Morra E; Larizza L
Exp Hematol; 2005 Jun; 33(6):682-8. PubMed ID: 15911092
[TBL] [Abstract][Full Text] [Related]
18. Analysis of signal transducer and activator of transcription 3 (STAT3) in gastrointestinal stromal tumors.
Paner GP; Silberman S; Hartman G; Micetich KC; Aranha GV; Alkan S
Anticancer Res; 2003; 23(3B):2253-60. PubMed ID: 12894500
[TBL] [Abstract][Full Text] [Related]
19. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells.
Mora LB; Buettner R; Seigne J; Diaz J; Ahmad N; Garcia R; Bowman T; Falcone R; Fairclough R; Cantor A; Muro-Cacho C; Livingston S; Karras J; Pow-Sang J; Jove R
Cancer Res; 2002 Nov; 62(22):6659-66. PubMed ID: 12438264
[TBL] [Abstract][Full Text] [Related]
20. STAT3 and MITF cooperatively induce cellular transformation through upregulation of c-fos expression.
Joo A; Aburatani H; Morii E; Iba H; Yoshimura A
Oncogene; 2004 Jan; 23(3):726-34. PubMed ID: 14737107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
